All News
Dr. Kevin Winthrop at #EULAR2019 during his infection lecture delivers the Pearl that Tofacitinib pts found to have Latent TB cannot take Rifampin - drug interaction w/ Tofa (lowers levels) https://t.co/LpoRbVC77J
Dr. John Cush RheumNow ( View Tweet)
Baricitinib long term clinical trial safety up to 7yrs #EULAR2019 https://t.co/jFKOrS28wz
Dr Irwin Lim _connectedcare ( View Tweet)
EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy
#EULAR2019 https://t.co/azj3ZPOxqb
ARD & RMD Open ARD_BMJ ( View Tweet)
In women with SLE on MMF, switch to AZA and wait 3 months prior to trying to conceive as some will flare with the switch. Catherine Nelson-Piercy. #EULAR2019
Rachel Black dr_rachelblack ( View Tweet)
Wellbeing measures in RA: a summary of Baracitinib vs Adalimumab #EULAR2019 https://t.co/0bYHLpzSrV
Dr Irwin Lim _connectedcare ( View Tweet)
ACR CRISS shows efficacy in ASSET (abatacept) trial in scleroderma. Another trial with positive CRISS. #EULAR2019 POSTER FR0327. @bmsnews https://t.co/6dTdehoAUe
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
Dr Nelson-Piercy illustrates drugs that can & can't be used during pregnancy. Win&Hot session #EULAR2019 @RheumNow https://t.co/C9g8tyBixj
Emilio Martin Mola emartinmola ( View Tweet)
So many factors contribute to disease activity. The scatterplot’s got scatter: at least for SpA, adalimumab drug concentrations are at most only one of those factors. #EULAR2019 FRI0381 from Groningen @RheumNow https://t.co/SaWg143ViT
David Liew drdavidliew ( View Tweet)
Busy day at Eular Madrid #EULAR2019 @RheumNow https://t.co/QB6vkbzvmW
Janet Pope Janetbirdope ( View Tweet)
Dr Alvin Wells - ACrossover Swithchiing study of the Jak inhibitor UPAdacitinib and adalimumab. OP0029. #EULAR2019 https://t.co/MqLtR8qmwJ
Dr. John Cush RheumNow ( View Tweet)
Dr. Atul Deodhar presents data showing that secukinumab treated ankylosing spondylitis patients respond better when treated early. #EULAR2019 FRI0388 https://t.co/7swe9vpRdl
Dr. John Cush RheumNow ( View Tweet)
Dr. Christopher Ritchlin - New Phenotypic and Biomarket Predictors of Psoriatic Arthritis. Presentations from #EULAR2019 https://t.co/Z4YRuJbr51
Dr. John Cush RheumNow ( View Tweet)
Pulse methylpred does not improve survival or relapse but is associated with increased morbidity in AAV. Raashid Luqmani. #EULAR2019 https://t.co/NJPvGyCO2l
Rachel Black dr_rachelblack ( View Tweet)
Rescreening for TB during bDMARDs might be a waste in a lot of countries, but in Romania it might be a different story (despite latent TB chemoprophylaxis). Infection risk depends on epidemiology #EULAR2019 FRI0076 @RheumNow https://t.co/2GuiW9oJkQ
David Liew drdavidliew ( View Tweet)
Dr. Artie Kavanaugh - New Prednisone Revelations from #EULAR2019 https://t.co/ChAjGJpjF2
Dr. John Cush RheumNow ( View Tweet)
Nordic collaboration registry data: Etanercept vs Etanercept-biosimilar in SpA
As expected, everything is SIMILAR
#EULAR2019 https://t.co/BvYTs7bJi6
Dr Irwin Lim _connectedcare ( View Tweet)
Receptor occupancy: sarilumab vs tocilizumab. Just going to leave this here without comment #EULAR2019 FRI0106 @RheumNow https://t.co/JFzWJw7phj
David Liew drdavidliew ( View Tweet)
We must indicate the #Influenza vaccination to all the TNFi treated patients.. Dr. Giovanni Adami (Italy) #EULAR2019 https://t.co/5Cg6MKXhfc
Dr.Martínez MtzReuma ( View Tweet)
@KarlGaffney1: extra-articular manifestations (EAMs) were present in 30% of people with #axialSpA in BSRBR-AS.
EAMs did not appear to influence decision to prescribe 1st biologic but uveitis and IBD did influence which TNFi was chosen (i.e.monoclonal TNFi)
#EULAR2019 https://t.co/3qSEPIvoxF
Stefan Siebert StefanSiebert1 ( View Tweet)
Quantitative magnetic resonance imaging T2 assessment of #muscle
➡️Could this be the future for detecting #myositis on #imaging?
Matt Farrow is ready to present his work from @LeedsBRC
👉🏼FRI0637 #EULAR2019
#MRI https://t.co/HZoAaZG1hW
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)